ORTHOCYTE CORPORATION – Trademark Portfolio

Entity Type: 03

ORTHOCYTE CORPORATION holds 6 U.S. trademarks filed with the United States Patent and Trademark Office (USPTO), with a strong focus on Class 1 (Chemicals) — 6 filings in this category. Currently, 5 trademarks are registered. Notable registered marks include HYSTEM, GELIN-S, GLYCOSIL, HEPRASIL, and EXTRALINK. The owner is based in ALAMEDA, CA.

1301 HARBOR BAY PARKWAY

ALAMEDA, CA 94502

6 Total Trademarks

Add to watchlist:

No watchlists yet
Loading...
By Date
By Name
Filter by Class:

EXTRACEL
EXTRACEL
Cancelled 2009
HYSTEM
HYSTEM
Registered 2009
GLYCOSIL
GLYCOSIL
Registered 2009
HEPRASIL
HEPRASIL
Registered 2009
GELIN-S
GELIN-S
Registered 2009
EXTRALINK
EXTRALINK
Registered 2009

Trademark Classifications

ORTHOCYTE CORPORATION's trademark portfolio spans 1 Nice Classification class, reflecting the scope of goods and services protected under their brand portfolio.

1
Chemicals (6 filings)

Chemical products for industry, science, photography, agriculture, horticulture and forestry

Frequently Asked Questions

How many trademarks does ORTHOCYTE CORPORATION have?

ORTHOCYTE CORPORATION has 6 U.S. trademarks filed with the USPTO. Of these, 5 registered, 1 cancelled.

What trademark classes does ORTHOCYTE CORPORATION file in?

ORTHOCYTE CORPORATION files trademarks across 1 Nice Classification class. The most active classes are Class 1 (Chemicals). Class 1 covers chemical products for industry, science, photography, agriculture, horticulture and forestry.

What are ORTHOCYTE CORPORATION's most well-known trademarks?

ORTHOCYTE CORPORATION's registered trademark portfolio includes well-known marks such as HYSTEM, GELIN-S, GLYCOSIL, HEPRASIL, and EXTRALINK. These are among 5 currently registered trademarks in the portfolio.

What is ORTHOCYTE CORPORATION's trademark registration success rate?

ORTHOCYTE CORPORATION has a 83% trademark registration rate, with 5 out of 6 resolved applications resulting in successful registration. Currently, 0 applications are pending review.